A delicate balancing act for Immunogen

Expect Immunogen to have had a busy weekend: for one, it will likely have been working the phones with its bankers after last week’s wounding setback for its lead asset, mirvetuximab. But discussions should also have turned to how Jazz Pharmaceuticals might be persuaded to opt in to two early assets, IMGN779 and IMGN632.